Amy McBride Wendell
Amy McBride Wendell's purchase track record
Amy McBride Wendell has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/10/2026 | SOLV | $100K | +22.0% | +33.3% | +13.2% |
| 9/6/2023 | AXGN | $62K | +18.7% | +47.3% | +14.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Baxter International publishes inaugural Connected Hospital Report. Baxter International released its first Connected Hospital Report, highlighting its role in remote cardiac monitoring and digital health infrastructure. The company is also featured in recent discussions regarding potential warning signs in Wall Street favorites and overlooked investment angles. These developments provide context for the stock's current position within its 52-week range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Solventum Featured in Yahoo’s Overrated and Profitable Stock Lists. Yahoo highlighted Solventum in two recent articles. In one piece it was listed among stocks that may be overvalued, while the other article named it a profitable long‑term option. The coverage may influence how investors view the company’s valuation and growth prospects. The stock remains near the middle of its 52‑week range.
Transaction History
| AXGN | ▲ Buy | Option Exercise | 13,353 | $198K | 8/11/2026 | View on chart |
| AXGN | ▼ Sell | Open Market | 13,353 | $647K | 8/11/2026 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 14,150 | $0 | 6/19/2026 | View on chart |
| AXGN | ▼ Sell | Open Market | 1,647 | $70K | 5/8/2026 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 1,647 | $24K | 5/8/2026 | View on chart |
| BAX | ▲ Buy | Grant | 12,836 | $0 | 5/5/2026 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 3,403 | $0 | 4/30/2026 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 1,980 | $0 | 3/27/2026 | View on chart |
| SOLV | ▲ Buy | Open Market | 1,475 | $100K | 3/10/2026 | View on chart |
| AXGN | ▼ Sell | Open Market | 18,248 | $535K | 12/16/2025 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 5,000 | $45K | 12/16/2025 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 20,436 | $129K | 12/16/2025 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 18,248 | $128K | 12/16/2025 | View on chart |
| AXGN | ▼ Sell | Open Market | 5,000 | $147K | 12/16/2025 | View on chart |
| AXGN | ▼ Sell | Open Market | 20,436 | $599K | 12/16/2025 | View on chart |
| AXGN | ▼ Sell | Open Market | 4,073 | $43K | 6/9/2025 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 3,564 | $0 | 5/13/2025 | View on chart |
| BAX | ▲ Buy | Grant | 7,183 | $0 | 5/6/2025 | View on chart |
| AXGN | ▼ Sell | Open Market | 5,000 | $100K | 3/3/2025 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 11,904 | $0 | 9/1/2024 | View on chart |
| AXGN | ▲ Buy | Grant | 10,653 | — | 6/6/2024 | View on chart |
| BAX | ▲ Buy | Grant | 5,952 | $0 | 5/7/2024 | View on chart |
| AXGN | ▲ Buy | Open Market | 10,000 | $62K | 9/6/2023 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 6,459 | $0 | 6/1/2023 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 25,000 | $231K | 5/12/2023 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 3,750 | $35K | 5/12/2023 | View on chart |
| BAX | ▲ Buy | Grant | 4,573 | $0 | 5/2/2023 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 3,036 | $0 | 6/1/2022 | View on chart |
| BAX | ▲ Buy | Grant | 2,706 | $0 | 5/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Axogen Receives New Analyst Coverage and Valuation Upside
Axogen has attracted new analyst coverage from Robinhood and B of A Securities, both issuing bullish notes and setting price targets around $52. A Yahoo analysis suggests the stock may be about 26% undervalued on cash‑flow grounds, while the company has fallen 22.6% in the past month. These developments highlight renewed investor interest and potential upside relative to recent price action.
Axogen Receives New Analyst Coverage and Valuation Upside. Axogen has attracted new analyst coverage from Robinhood and B of A Securities, both issuing bullish notes and setting price targets around $52. A Yahoo analysis suggests the stock may be about 26% undervalued on cash‑flow grounds, while the company has fallen 22.6% in the past month. These developments highlight renewed investor interest and potential upside relative to recent price action.